• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Strides Pharma Science Limited — Updates, 30-01-2026: General Updates

    30-01-2026 | 12:57 pm

    Strides Pharma posted record Q3FY26 EBITDA of ₹235.9 Cr (+12.2% YoY) and Operational PAT of ₹128.2 Cr (+38.6% YoY). Ex-US business grew 20% YoY, offsetting flat US ops. Net debt decreased to ₹1,435.8 Cr. Peter Hardwick appointed North America CEO.

    No comments yet. Be the first to comment!

    All announcements from Strides Pharma Science Limited